NEXTES, which operates its proprietary battery control technology brand “ACTIVA,” raises ¥2 billion! C4U, which is developing “CRISPR-Cas3,” a genome-editing technology for medical drug discovery, raises ¥1.2 billion in a Series C round! [Latest Startup News] | News
NEXTES, which operates its proprietary battery control technology brand “ACTIVA,” raises ¥2 billion! C4U, which is developing “CRISPR-Cas3,” a genome-editing technology for medical drug discovery, raises ¥1.2 billion in a Series C round! [Latest Startup News]
Read in fullFrom the source, not the headline
1
sources corroborateOutlets reporting the same event
0
companies linkedAcross 0 themes, second pass
The story
No summary is published for this storyThe automatic check found assertive wording, so the summary is withheld. The sources and linked themes are still shown.
Where this came from
We read each source in full and checked they agree on the core claim.